RT Journal Article SR Electronic T1 The evidence for magnetic resonance imaging as an outcome measure in proof-of-concept rheumatoid arthritis studies. JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP 2465 OP 2469 VO 32 IS 12 A1 Conaghan, Philip G A1 McQueen, Fiona M A1 Peterfy, Charles G A1 Lassere, Marissa N D A1 Ejbjerg, Bo A1 Bird, Paul A1 O'Connor, Philip J A1 Haavardsholm, Espen A1 Edmonds, John P A1 Emery, Paul A1 Genant, Harry K A1 Ostergaard, Mikkel A1 , YR 2005 UL http://www.jrheum.org/content/32/12/2465.abstract AB Magnetic resonance imaging (MRI) has now been used extensively in cross-sectional and observational studies as well as in controlled clinical trials to assess disease activity and joint damage in rheumatoid arthritis (RA). MRI measurements or scores for erosions, bone edema, and synovitis have been developed and validated by several groups. The OMERACT criteria require that outcome measures demonstrate adequate validity, discriminative power, and feasibility if they are to be useful in clinical trials. Specific performance targets for these criteria depend on the scientific, regulatory, logistical, and financial context of the study in question. We review the extent to which MRI assessments of joint erosion, bone edema, and synovitis fulfil these criteria, particularly as they relate to proof-of-concept RA clinical trials.